Dyne Therapeutics Shares Rise After Amendment to Debt Facility
By Chris Wack
Dyne Therapeutics shares were 7% higher, at $19.34, after the company said it entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital.
The clinical-stage company said the transaction further strengthens its balance sheet as it advances zeleciment rostudirsen for exon 51 Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1.
Under the terms of the amendment, $50 million was funded upon execution of the amendment, and an additional term loan tranche for $50 million that can be drawn at Dyne's option subject to the achievement of certain milestones was added to the term loan facility.
The final term loan tranche was also increased by $25 million to provide up to an additional $75 million, which may be funded upon request of Dyne and at the discretion of Hercules Capital.
Dyne said that including the $50 million funded upon execution of the amendment, it has borrowed $200 million in loan proceeds in three tranches under the term loan facility and maintains access to up to $200 million in potential future funding under the facility.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 17, 2026 10:31 ET (14:31 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States